Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease.

Alimentary pharmacology & therapeutics - 1 Oct 2002

Ansari A, Hassan C, Duley J, Marinaki A, Shobowale-Bakre E-M, Seed P, Meenan J, Yim A, Sanderson J

Abstract excerpt

BACKGROUND: Azathioprine therapy is discontinued in one-third of patients with inflammatory bowel disease because of toxicity or a lack of clinical response. Patients with thiopurine methyltransferase (TPMT) deficiency are intolerant to azathioprine, whilst carriers are at increased risk of side-effects. AIM: To evaluate the importance of TPMT activity in the management of azathioprine therapy in inflammatory...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azathioprine
Share to Erythrocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunosuppressive Agents

Share to Inflammatory Bowel Diseases

Share to Leukocyte Count

Share to Logistic Models

Share to Methyltransferases

Share to Treatment Failure

Source

Identifiers

PMID: 12269967
DOI: 10.1046/j.1365-2036.2002.01353.x

Genes

TPMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease.PMID 12269967Read ↗

Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease.Semantic proximity Read ↗

High prevalence of polymorphism and low activity of thiopurine methyltransferase in patients with inflammatory bowel disease.Semantic proximity Read ↗

Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease.Semantic proximity Read ↗

The impact of thiopurine-S-methyltransferase genotype on the adverse drug reactions to azathioprine in patients with inflammatory bowel diseases.Semantic proximity Read ↗

A pharmacogenetics study of TPMT and ITPA genes detects a relationship with side effects and clinical response in patients with inflammatory bowel disease receiving Azathioprine.Semantic proximity Read ↗

Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease.Semantic proximity Read ↗

Glutathione-S-transferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel disease.Semantic proximity Read ↗

Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease PatientsSemantic proximity Read ↗

Limitations of extensive TPMT genotyping in the management of azathioprine-induced myelosuppression in IBD patients.Semantic proximity Read ↗

TPMT and ITPA genetic variants in Lithuanian inflammatory bowel disease patients: Prevalence and azathioprine-related side effects.Semantic proximity Read ↗

Thiopurine Drugs in the Treatment of Ulcerative Colitis: Identification of a Novel Deleterious Mutation in TPMT.Semantic proximity Read ↗

Effective long-term solution to therapeutic remission in Inflammatory Bowel Disease: Role of Azathioprine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.